MedTrace Logo

Transversus Abdominis Plane (TAP) Block Using Liposomal Bupivacaine in Metabolic and Bariatric Surgery Patients

NCT05537883 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-06-11

Study results available
· View outcomes & findings →

Summary

To investigate if laparoscopic Transversus Abdominis Plane (TAP) block using plain bupivacaine is equivalent to using liposomal bupivacaine in patients undergoing metabolic and bariatric surgery. The study will see if the plain bupivacaine group will be equivalent in terms of length of stay, Morphine Milligram Equivalents, Pain scores and patient satisfaction, but cost less.

Conditions

  • Morbid Obesity
  • Bariatric Surgery Candidate

Interventions

DRUG

Liposomal bupivacaine

Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with liposomal bupivacaine

DRUG

Bupivacaine Injection

Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with plain bupivacaine

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Abdelrahman Nimeri, MD · Wake Forest University Health Sciences, Atrium Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-29
Primary Completion
2023-12-07
Completion
2023-12-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05537883 on ClinicalTrials.gov